Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Erben

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
Journal of Cancer Research and Clinical Oncology|September 24, 2013
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 studyAndreas Hochhaus, Philipp D le Coutre, Hagop M Kantarjian, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2010
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancerPhilipp Erben, Philipp Ströbel, Karoline Horisberger, et al.
Frontiers in Oncology|June 13, 2024
Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancerDaniel Uysal, Blerta Thaqi, Alexander Fierek, et al.
Scientific Reports|September 28, 2018
CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-makingThomas S Worst, Cleo-Aron Weis, Robert Stöhr, et al.
EMBO Reports|March 24, 2026
The bladder cancer m<sup>6</sup>A landscape is defined by global methylation dilution and focal 3'-UTR hypermethylationJonas Koch, Jinyun Xu, Felix Bormann, et al.
Anticancer Research|May 7, 2013
Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitroChristoph Aderhold, Claudia Umbreit, Anne Faber, et al.
BMC Cancer|August 23, 2011
Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapyJuliana Schwaab, Karoline Horisberger, Philipp Ströbel, et al.
Virchows Archiv : an International Journal of Pathology|August 13, 2016
ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC)Johannes Breyer, Ralph M Wirtz, Mark Laible, et al.
BJU International|August 19, 2018
FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancerJohannes Breyer, Ralph M Wirtz, Philipp Erben, et al.
Oncotarget|October 6, 2017
Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsiesJohannes Breyer, Ralph Markus Wirtz, Wolfgang Otto, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Journal of Cancer Research and Clinical Oncology|September 24, 2013
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 studyAndreas Hochhaus, Philipp D le Coutre, Hagop M Kantarjian, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2010
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancerPhilipp Erben, Philipp Ströbel, Karoline Horisberger, et al.
Frontiers in Oncology|June 13, 2024
Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancerDaniel Uysal, Blerta Thaqi, Alexander Fierek, et al.
Scientific Reports|September 28, 2018
CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-makingThomas S Worst, Cleo-Aron Weis, Robert Stöhr, et al.
EMBO Reports|March 24, 2026
The bladder cancer m<sup>6</sup>A landscape is defined by global methylation dilution and focal 3'-UTR hypermethylationJonas Koch, Jinyun Xu, Felix Bormann, et al.
Anticancer Research|May 7, 2013
Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitroChristoph Aderhold, Claudia Umbreit, Anne Faber, et al.
BMC Cancer|August 23, 2011
Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapyJuliana Schwaab, Karoline Horisberger, Philipp Ströbel, et al.
Virchows Archiv : an International Journal of Pathology|August 13, 2016
ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC)Johannes Breyer, Ralph M Wirtz, Mark Laible, et al.
BJU International|August 19, 2018
FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancerJohannes Breyer, Ralph M Wirtz, Philipp Erben, et al.
Oncotarget|October 6, 2017
Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsiesJohannes Breyer, Ralph Markus Wirtz, Wolfgang Otto, et al.
Pageof 13